You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 7,998,506


✉ Email this page to a colleague

« Back to Dashboard


Title:Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
Abstract: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally," that is in the evening or at night.
Inventor(s): Bova; David J (Boca Raton, FL)
Assignee: KOS Life Sciences, Inc. (Weston, FL)
Filing Date:May 23, 2003
Application Number:10/444,145
Claims:1. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 375 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs.

2. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 500 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs.

3. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 750 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs.

4. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 1000 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.